65
report
Creating a Nonprofit Marketplace for Shelved Drugs: Lessons from a Pilot Project
Many promising medicines, despite strong safety data and pharmaceutical characteristics, are discon
tinued by drug companies for nonscientific reasons, including strategic, organizational, and financial considerations.
+ Read More
report
Hedging Pipeline Risk in Pharma: FDA Swaps and Annuities
The cost of capital to conduct medical R&D is high because investors must be compensated with s
ignificant returns to offset the risky and long drug-development process.
+ Read More
report
Nonprofits: A Growing Force in Drug Development
Shepherding a drug from discovery to the market is a complex process that involves many actors.
report
Patient-Focused Drug Development Meetings: Smart Practices from Community Leaders
FasterCures, a center of the Milken Institute, designed this guide for patient advocacy organizatio
ns that are interested in hosting, or are currently planning, an externally led patient-focused drug development (PFDD)
+ Read More
report
GBM: Giving Smarter
Glioblastoma Multiforme (GBM) is an aggressive malignant brain tumor involving glial cells of the b
rain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe.
+ Read More
report
State Technology and Science Index 2016: Sustaining Americas Innovation Economy
As the Great Recession recedes in our rearview mirrors, it is becoming ever more apparent that inno
vative activities are determining an increasing proportion of the long-term economic growth of cities, metropolitan areas, regions, states, and even natio
+ Read More
report
Models for Financing Antibiotic Development to Address Antimicrobial Resistance
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to id
report
Demographic Reporting and Mix in Clinical Trials
Clinical trial enrollment can vary based on demographics. Cancer drug trials, for example, have bee
n shown to skew disproportionately toward young, White, male participants.
+ Read More
podcast episode
Ep. 34: Upside Down, with Vivek Ramaswamy
“Seeing my own family members in New York go through what they're going through has...not only tur
ned our personal life upside down, but also has turned upside down...the near-term priorities of our company to help do our part in addressing this
+ Read More
podcast episode
Ep. 10: The Public Servant, with former FDA Commissioner Margaret Hamburg
“I always said it was a question of when, not if, we would have to combat a global pandemic.
podcast episode
Ep. 109: Lessons Learned: the Intersection of Cancer Research and COVID Treatments
“The road to curing COVID runs right through lots and lots of cancer research.” - Jonathan Simons,
President and CEO, Prostate Cancer Foundation
+ Read More
video
A Conversation with Pfizer CEO Albert Bourla and J&J CEO Alex Gorsky
December 7 at 9 am PT/12 pm ET
This session was recorded on Thursday, December 3.